Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

May 31, 2015

Conditions
Failure of Bone Marrow Graft
Interventions
DRUG

Plerixafor

Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.

Trial Locations (2)

27705

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Mitchell Horwitz, MD

OTHER

NCT01280955 - Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant | Biotech Hunter | Biotech Hunter